Latest PromarkerD clinical validation results published in the Journal of Diabetes and its...
Proteomics International Laboratories (ASX:PIQ) receives $1.2 million R&D incentive – The Market Herald
“Study results have shown PromarkerD can outperformed the current tests used to predicting the onset of diabetic kidney disease during a four-year follow-up period.“
“The company says it will continue to invest in its biomarker discovery program centred on the Promarker™ technology platform.“
Article: Proteomics International Laboratories (ASX:PIQ) receives $1.2 million R&D incentive